Fuse Vectors is pioneering a transformative approach to gene therapy through its innovative cell-free viral vector technology, specifically focusing on Adeno-Associated Virus (AAV) vectors. Traditional cell-based methods for producing AAVs often lead to inefficiencies, high toxicity, and elevated production costs, which hinder the development of effective gene therapies. In contrast, Fuse Vectors employs its proprietary Fuse Technology, which allows for the production of AAVs outside of living cells. This method ensures 100% purity of the AAV product in a single step, significantly enhancing the therapeutic efficacy and safety of gene therapies.

The company's Fuse Optimization Engine further enhances its capabilities by enabling rapid prototyping and testing of AAV drug candidates. This modular approach, facilitated by the Fuse Foundry library, allows for scalable production and accelerates the research and development process. By lowering the barriers to entry for gene therapy production, Fuse Vectors aims to democratize access to these advanced therapies, making them available for a wider range of genetic illnesses. Overall, Fuse Vectors is committed to revolutionizing the gene therapy landscape by providing a more efficient, safer, and cost-effective solution for AAV development.

Denmark

At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time.

Fuse Vectors

Company Details